DexCom (DXCM) Set to Announce Earnings on Thursday

DexCom (NASDAQ:DXCM) is scheduled to release its earnings data after the market closes on Thursday, April 25th. Analysts expect DexCom to post earnings of $0.27 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the company earned $0.34 EPS. The firm’s quarterly revenue was up 26.9% on a year-over-year basis. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Stock Down 1.9 %

Shares of NASDAQ:DXCM opened at $133.86 on Thursday. The stock’s 50-day moving average price is $129.20 and its two-hundred day moving average price is $116.28. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. DexCom has a 12-month low of $74.75 and a 12-month high of $142.00. The firm has a market cap of $51.61 billion, a price-to-earnings ratio of 102.18, a PEG ratio of 2.31 and a beta of 1.20.

Insider Activity

In other news, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the sale, the chief operating officer now directly owns 273,913 shares in the company, valued at approximately $36,816,646.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Jacob Steven Leach sold 14,639 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the transaction, the chief operating officer now directly owns 273,913 shares in the company, valued at approximately $36,816,646.33. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DXCM. FIL Ltd boosted its position in DexCom by 121.5% during the 4th quarter. FIL Ltd now owns 186,362 shares of the medical device company’s stock worth $23,126,000 after acquiring an additional 102,213 shares during the period. SageView Advisory Group LLC acquired a new position in DexCom during the 4th quarter worth $344,000. Sanibel Captiva Trust Company Inc. acquired a new position in DexCom during the 4th quarter worth $1,791,000. Harbour Investments Inc. boosted its position in DexCom by 493.8% during the 4th quarter. Harbour Investments Inc. now owns 1,995 shares of the medical device company’s stock worth $248,000 after acquiring an additional 1,659 shares during the period. Finally, O Dell Group LLC acquired a new position in DexCom during the 4th quarter worth $54,000. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DXCM shares. UBS Group lifted their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Raymond James boosted their price target on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Finally, Citigroup boosted their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.